肝癌组织Bcl-2的检测及小干扰RNA抑制

Detection of Bcl-2 in human hepatocellular carcinoma and down-regulation with siRNA

目的探究肝癌组织中Bcl-2的表达与肝癌临床病理特征、患者预后之间的关系;观察siRNA抑制Bcl-2表达后,SMMC-7721增殖能力的变化。方法通过反转录PCR、免疫组织化学SP法以及Western blot法检测68例肝癌组织中Bcl-2的表达;根据Bcl-2表达水平的高低进行分组,比较不同组中肝癌临床病理特征及患者预后;通过siRNA抑制Bcl-2在SMMC-7721细胞中的表达,应用MTT法检测细胞增殖能力的变化。结果相较于癌旁组织,Bcl-2肝癌中表达明显升高;Bcl-2在肝癌组织中表达水平与肝癌临床病理特征存在明显相关性,Bcl-2表达水平较高的患者预后较差;siRNA抑制SMMC-7721细胞中Bcl-2的表达后细胞增殖能力显著降低。结论 Bcl-2的表达在肝癌组织中异常增高,且与肝癌临床病例特征及患者预后存在相关性;抑制Bcl-2的表达可降低肝癌细胞的增殖能力。

Objective To investigate the relationship between the level of Bcl-2 in human hepatocellular carcinoma （HCC） tissues and the clinicopathological characteristics and prognosis of patients, and to detect the proliferation of SMMC-7721 cells after Bcl-2 is down-regulated with siRNA. Methods The level of Bcl-2 in 68 HCC tissues was detected by reverse transcription PCR, SP immunohistochemistry and Western blotting. The 68 HCC tissues were divided into two groups based on the level of Bcl-2. The clinicopathological characteristics and prognosis of the patients were compared between groups. The proliferation of SMMC-7721 cells was evaluated by MTI assay after Bcl-2 was inhibited with siRNA. Results Compared with corresponding noncancerous liver tissues, the level of Bcl-2 was significantly elevated in HCC tissues. The level of Bcl-2 was correlated with clinicopathological characteristics, and the patient with higher expression level of Bcl-2 had relatively poorer prognosis. Down-regulation of Bcl-2 expression by siRNA significantly inhibited the proliferation of SMMC-7721 cells. Conclusion The level of Bcl-2 is abnormally elevated in HCC tissues and can serve as a predictor of the prognosis of patients with HCC. The down-regulated of Bcl-2 in SMMC-7721 cells can inhibit the proliferation of cancer cells.